Skye Bioscience (SKYE) Stock Forecast & Price Target

Compare

931 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SKYE Analyst Ratings

Strong Buy

4 Buy

1 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Skye

Bioscience

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SKYE Stock 12 Month Forecast

Average Price Target

$14.33

▲(1424.47% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Skye Bioscience in the last 3 months. The average price target is $14.33 with a high forecast of $20.00 and a low forecast of $10.00. The average price target represents a 1424.47% change from the last price of $0.94.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","21":"$21","-1":"-$1","4.5":"$4.5","15.5":"$15.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,4.5,10,15.5,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.749,2.229846153846154,3.710692307692308,5.191538461538461,6.672384615384615,8.15323076923077,9.634076923076924,11.114923076923079,12.595769230769232,14.076615384615385,15.55746153846154,17.038307692307693,18.519153846153845,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.749,1.7936923076923077,2.8383846153846153,3.883076923076923,4.92776923076923,5.972461538461538,7.017153846153845,8.061846153846153,9.106538461538461,10.15123076923077,11.195923076923076,12.240615384615383,13.285307692307692,{"y":14.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.749,1.4606153846153846,2.172230769230769,2.8838461538461537,3.5954615384615383,4.307076923076923,5.018692307692307,5.730307692307691,6.441923076923076,7.153538461538461,7.865153846153845,8.57676923076923,9.288384615384615,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.28,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.83,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.21,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.41,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.38,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.26,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.21,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.749,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$20.00

Average Price Target$14.33

Lowest Price Target$10.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ananda Ghosh

H.C. Wainwright

$20

Buy

2027.66%

Upside

Reiterated

01/06/26

Skye Bioscience: ENHANZE Partnership Unlocks Nimacimab Dosing, De-Risks Phase 2b Path and Supports Buy Rating

Jay Olson

Oppenheimer

$10

Buy

963.83%

Upside

Reiterated

11/12/25

Oppenheimer Sticks to Their Buy Rating for Skye Bioscience (SKYE)

Albert Lowe

Craig-Hallum

Hold

―

Reiterated

11/12/25

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (NASDAQ: VYGR) and Skye Bioscience (NASDAQ: SKYE)

Andy Hsieh

William Blair

Buy

―

Reiterated

11/11/25

Analysts' Top Healthcare Picks: Maravai Lifesciences Holdings (MRVI), Assembly Biosciences (ASMB)

Edward Tenthoff

Piper Sandler

$13

Buy

1282.98%

Upside

Reiterated

11/11/25

Skye Bioscience (SKYE) Receives a Buy from Piper Sandler

Kristen Kluska

Cantor Fitzgerald

$14→$2

Hold

112.77%

Upside

Downgraded

10/06/25

Skye Bioscience downgraded to Neutral from Overweight at Cantor FitzgeraldSkye Bioscience downgraded to Neutral from Overweight at Cantor Fitzgerald

Jonathan Wolleben

Citizens JMP

$16→$4

Buy

325.53%

Upside

Reiterated

10/06/25

Citizens JMP Remains a Buy on Skye Bioscience (SKYE)

Michael DiFiore

Evercore ISI

$10

Buy

963.83%

Upside

Initiated

08/15/25

Skye Bioscience initiated with an Outperform at Evercore ISISkye Bioscience initiated with an Outperform at Evercore ISI

George Farmer

Scotiabank

$20

Buy

2027.66%

Upside

Reiterated

05/09/25

Scotiabank Sticks to Their Buy Rating for Skye Bioscience (SKYE)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ananda Ghosh

H.C. Wainwright

$20

Buy

2027.66%

Upside

Reiterated

01/06/26

Skye Bioscience: ENHANZE Partnership Unlocks Nimacimab Dosing, De-Risks Phase 2b Path and Supports Buy Rating

Jay Olson

Oppenheimer

$10

Buy

963.83%

Upside

Reiterated

11/12/25

Oppenheimer Sticks to Their Buy Rating for Skye Bioscience (SKYE)

Albert Lowe

Craig-Hallum

Hold

―

Reiterated

11/12/25

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (NASDAQ: VYGR) and Skye Bioscience (NASDAQ: SKYE)

Andy Hsieh

William Blair

Buy

―

Reiterated

11/11/25

Analysts' Top Healthcare Picks: Maravai Lifesciences Holdings (MRVI), Assembly Biosciences (ASMB)

Edward Tenthoff

Piper Sandler

$13

Buy

1282.98%

Upside

Reiterated

11/11/25

Skye Bioscience (SKYE) Receives a Buy from Piper Sandler

Kristen Kluska

Cantor Fitzgerald

$14→$2

Hold

112.77%

Upside

Downgraded

10/06/25

Skye Bioscience downgraded to Neutral from Overweight at Cantor FitzgeraldSkye Bioscience downgraded to Neutral from Overweight at Cantor Fitzgerald

Jonathan Wolleben

Citizens JMP

$16→$4

Buy

325.53%

Upside

Reiterated

10/06/25

Citizens JMP Remains a Buy on Skye Bioscience (SKYE)

Michael DiFiore

Evercore ISI

$10

Buy

963.83%

Upside

Initiated

08/15/25

Skye Bioscience initiated with an Outperform at Evercore ISISkye Bioscience initiated with an Outperform at Evercore ISI

George Farmer

Scotiabank

$20

Buy

2027.66%

Upside

Reiterated

05/09/25

Scotiabank Sticks to Their Buy Rating for Skye Bioscience (SKYE)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Skye Bioscience

3 Months

xxx

Success Rate

2/8 ratings generated profit

Average Return

-2.45%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 25.00% of your transactions generating a profit, with an average return of -2.45% per trade.

1 Year

Jay OlsonOppenheimer

Success Rate

1/11 ratings generated profit

Average Return

-54.62%

reiterated a buy rating 2 months ago

Copying Jay Olson's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -54.62% per trade.

2 Years

xxx

Success Rate

0/8 ratings generated profit

Average Return

-57.24%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -57.24% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SKYE Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SKYE has received 6 Buy Ratings, 6 Hold Ratings, and 1 Sell Ratings. SKYE average Analyst price target in the past 3 months is 14.33.

Each month's total comprises the sum of three months' worth of ratings.

SKYE Financial Forecast

SKYE Earnings Forecast

Next quarter’s earnings estimate for SKYE is -$0.30 with a range of -$0.36 to -$0.20. The previous quarter’s EPS was -$0.32. SKYE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year SKYE has Performed in-line its overall industry.

No data currently available

SKYE Sales Forecast

Next quarter’s sales forecast for SKYE is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. SKYE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year SKYE has Performed in-line its overall industry.

SKYE Stock Forecast FAQ

What is SKYE’s average 12-month price target, according to analysts?

Based on analyst ratings, Skye Bioscience’s 12-month average price target is 14.33.

What is SKYE’s upside potential, based on the analysts’ average price target?

Skye Bioscience has 1424.47% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SKYE a Buy, Sell or Hold?

Skye Bioscience has a consensus rating of Strong Buy which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.

What is Skye Bioscience’s price target?

The average price target for Skye Bioscience is 14.33. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $10.00. The average price target represents 1424.47% Increase from the current price of $0.94.

What do analysts say about Skye Bioscience?

Skye Bioscience’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of SKYE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Skye Bioscience (SKYE) Stock Forecast & Price Target

SKYE Analyst Ratings

SKYE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Skye Bioscience

SKYE Analyst Recommendation Trends

SKYE Financial Forecast

SKYE Earnings Forecast

SKYE Sales Forecast

SKYE Stock Forecast FAQ

Detailed List of Analyst Forecasts